Table 4 Differentially expressed autoantibodies between RA patients and healthy controls, adjusted for age and gender.

From: Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients

Protein

Coefficient

95% confidence interval

p-value

Adjusted p-value (Benjamini–Hochberg correction)

ASMTL_c

3.41

2.50–4.33

4.66E–12

<1E–07

EIF4H_c

2.72

1.94–3.51

9.09E–11

<1E–07

SPP1_c

2.05

1.43–2.67

5.53E–10

<1E–07

NONO_c

2.11

1.45–2.78

2.43E–09

<1E–07

CLU_c

1.87

1.25–2.49

1.42E–08

1E–06

VIM_c

2.52

1.67–3.37

2.46E–08

1E–06

FN1_c

1.71

1.11–2.31

6.93E–08

2E–06

CPSF6_c

2.17

1.41–2.93

7.55E–08

2E–06

TRA2B_c

1.39

0.86–1.93

7.54E–07

1.50E–05

RBMS1_c

1.61

0.99–2.24

9.58E–07

1.70E–05

ACTB_c

1.01

0.61–1.41

1.93E–06

3.20E–05

HNRNPA1_c

1.45

0.85–2.06

4.42E–06

6.70E–05

DNAJB1_c

1.38

0.76–2.01

2.24E–05

3.12E–04

TNC_c

1.18

0.62–1.74

4.92E–05

6.37E–04

FGB_c

0.92

0.45–1.39

1.64E–04

1.98E–03

SFPQ_c

1.12

0.52–1.72

3.03E–04

3.43E–03

SRSF7_c

0.77

0.35–1.19

3.57E–04

3.68E–03

TUBB_c

0.72

0.33–1.12

3.66E–04

3.68E–03

PADI4_c

0.69

0.31–1.06

4.50E–04

4.28E–03

AEBP1_c

0.91

0.36–1.46

1.39E–03

1.26E–02

DDX5_c

0.81

0.31–1.31

1.66E–03

1.43E–02

TNFSF13

−1.17

−1.94–(−0.39)

2.62E–03

2.98E–02

APOE_c

0.86

0.27–1.44

4.31E–03

3.26E–02

RBM39_c

0.61

0.20–1.02

4.32E–03

3.26E–02

IL1B

0.53

0.17–0.89

4.53E–03

3.27E–02

TUBB

0.56

0.17–0.94

4.69E–03

3.27E–02

FGA_c

0.53

0.16–0.91

5.73E–03

3.84E–02

IGF1_c

0.60

0.18–1.03

6.11E–03

3.91E–02

FEN1_c

0.66

0.19–1.12

6.40E–03

3.91E–02

ENO1_c

0.87

0.25–1.48

6.48E–03

3.91E–02

MMP2

0.48

0.13–0.82

7.05E–03

4.12E–02

OBSL1

0.49

0.13–0.84

7.73E–03

4.37E–02

HIST1H4A_c

0.48

0.13–0.83

8.32E–03

4.56E–02

PTBP1_c

0.67

0.17–1.17

9.07E–03

4.83E–02

Back to article page